Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population

Table 3 Clinical values over time of response variables after PAE

Variable	1 Mo (n = 105)	3 Mo (n = 105)	6 Mo (n = 105)	12 Mo (n = 94)	24 Mo (n = 84)
Variable	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	PValues
Age(year)	71.5 ± 12.5	71.5 ± 12.5	71.5 ± 12.5	72.5 ± 11.5	70.5 ± 11.0	_
IPSS(point)	9.5 ± 5.5	8.5 ± 3.0	7.5 ± 4.0	8.0 ± 4.5	9.0 ± 5.5	<0.01
QoL score	2.5 ± 1.0	3.0 ± 0.5	3.0 ± 1.0	2.5 ± 1.5	3.0 ± 1.0	<0.01
PV (mL)	103.8 ± 30.0	72.5 ± 25.0	70.0 ± 15.0	68.5 ± 15.0	69.0 ± 18.0	<0.01
Qmax (mL/s)	14.0 ± 3.5	15.0 ± 4.5	15.5 ± 6.5	14.5 ± 5.0	14.5 ± 3.5	<0.01
PVR (mL)	45.0 ± 20.0	40.0 ± 25.0	35.0 ± 15.0	40.0 ± 20.0	40.0 ± 15.0	<0.01
IIEF-5 (point)	11.0 ± 5.0	10.0 ± 4.0	12.0 ± 3.0	13.0 ± 2.0	10.0 ± 2.5	0.6

IIEF-5 = International Index of Erectile Function short form, IPSS = International Prostate Symptom Score, PSA = prostatic specific antigen, PV = prostate volume, PVR = postvoid residual urine, Q_max=peak urinary flow rate, QoL = quality of life.

ISSN: 1471-2490